

DETAILED ACTION

Claims 8 and 10-17 are pending in the instant application.

Amendments

The amendment filed on March 2, 2010 has been acknowledged and has been entered into the instant application file.

Previous Claim Objections

Claims 12 was previously objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The claim is no longer dependent on a rejected base claim, and the objection is withdrawn.

Claim 13 was previously objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim.

The claim has been rewritten in independent form, and the objection is withdrawn.

Previous Claim Rejections - 35 USC § 103

Claims 1, 5-8, 10, 11, 13, and 14 were previously rejected under 35 U.S.C. 103(a) as being unpatentable over Albert et al. (WO 02/38561 A1).

The declaration submitted by the Applicant has been considered and has been found to be persuasive. The rejection is withdrawn.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Richard Elder on June 1, 2010.

The application has been amended as follows:

In claim 10, line 1, delete "preventing or".

In claim 11, line 1, delete "preventing or".

In claim 16, line 1, delete "preventing or".

In claim 16, line 2, delete "diseases" and insert --diseases, wherein the T-cell-mediated inflammatory or autoimmune disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II, asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, seborrhoeic dermatitis, Sjoegren's syndrome, keratoconjunctivitis, uveitis, inflammatory bowel disease, Crohn's disease, and ulcerative colitis,---.

In claim 17, line 1, delete "preventing or".

In claim 17, line 2, delete "diseases" and insert --diseases, wherein the T-cell-mediated inflammatory or autoimmune disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's

Art Unit: 1626

thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II, asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, seborrhoeic dermatitis, Sjoegren's syndrome, keratoconjunctivitis, uveitis, inflammatory bowel disease, Crohn's disease, and ulcerative colitis,---.

Conclusion

Claims 8 and 10-17 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph R. Kosack whose telephone number is (571)272-5575. The examiner can normally be reached on M-Th 6:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571)-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Joseph R Kosack/
Primary Examiner, Art Unit 1626